Head of Signal—biopharma intelligence at FT's @endpts. Former Bloomberg & still keeping tabs on future of energy+transport. Opinions are, too often, my own.
The structural change to oil prices from the Iran war so far amounts to a ~$750 incentive for EV ownership over the next five years
https://t.co/vn3I3ZSZyr
Here's an updated look at the oil futures curve today vs. 1 month ago. You can see it's just a massive structural change. Even Brent for delivery in 2029 is way more expensive than it was
It takes about 15k miles of driving to make up for the additional manufacturing emissions — a bit more without battery recycling (but all EV batteries are being recycled).
For the average vehicle life, there's a 70% reduction in total lifecycle emissions. https://t.co/AIIXE9dTo7
Every time the quantity of batteries in the world doubles, prices fall 18%. This experience curve is one of the most consistent, and consequential, guideposts for predicting the future of energy and transportation.
Battery prices at $108/kWh is wild to see. That's the global average for all-in pack prices. In China, where EV and solar+battery adoption continues to rip, pack prices are down to $84/kWh. Latest figures from BNEF:
https://t.co/3FPLG1iEuB
A year from now, if the biopharma industry finds itself on much more solid footing, we may look back at this as the moment the gloom finally lifted.
https://t.co/AlWk2hP8eM
During the two weeks that our biopharma sentiment survey was in the field in mid-October, something unusual happened: The mood of the industry appeared to snap out of its despair, all at once. Our survey caught it real time.
Experience with AI matters a great deal for how quickly people think drug development will evolve: 90% of extensive users see transformational change in five years versus just 18% of people who don't use AI today https://t.co/3ETT8XFdMh
Three quarters of people in biopharma expect AI to transform drug R&D by 2030 — and 12% think we’ll get there even sooner, in just three years.
Already 48% are heavy users of AI in their daily work, according to our latest pulse poll.
@BowTiedBiotech I've been elbows-deep building tools and mapping out the benchmark products that will define @endpts Signal—and I can't wait to share what's coming. Let me know what you think https://t.co/5lrMhJ6NH8
https://t.co/FASsOfAguv
Some long-overdue news. After years covering EVs, batteries & the energy transition, I’m shifting gears. I’ve joined @Endpts News as Head of Signal — building a new intelligence platform from scratch. Back to my roots in the weird, brilliant, high-stakes world of drug science🧬1/
Introducing the Biopharma Sentiment Index, a quarterly benchmark measuring the mood of the industry. It includes the viewpoints of 1,457 verified respondents, a quarter of whom are C-level execs. Current conditions? Brutal. Future expectations: Better. The BPSI shows why
@BowTiedBiotech There’s a lot more to explore in the BPSI — I’d love to hear what you think. This is just setting the baseline. Future installments will show how sentiment changes over time and how those changes anticipate other metrics of industry performance 7/ https://t.co/PNVFjrouo0
Some long-overdue news. After years covering EVs, batteries & the energy transition, I’m shifting gears. I’ve joined @Endpts News as Head of Signal — building a new intelligence platform from scratch. Back to my roots in the weird, brilliant, high-stakes world of drug science🧬1/